ReportWire

Tag: Digestive Disorders

  • Young Adults With IBD Face Insurance, Cost Barriers To Care, Survey Finds

    [ad_1]

    By Dennis Thompson HealthDay ReporterTUESDAY, Jan. 6, 2026 (HealthDay News) — Young adults are having a tough time accessing treatment for their inflammatory bowel disease (IBD), a new study says.

    They are more likely to face insurance barriers and financial strain to get proper care for their IBD, researchers reported today in the journal Crohn’s & Colitis 360.

    “These numbers demonstrate a clear gap in support and guidance for young adults as they transition from pediatric care and begin managing their own health insurance,” said Laura Wingate, chief education, support and advocacy officer at the Crohn’s & Colitis Foundation.

    “The data show that not only are younger patients at greater risk of having to jump through insurance hoops to access essential medications, they also face substantial financial pressure — often working extra jobs just to afford care,” she said in a news release.

    For the study, the Crohn’s & Colitis Foundation surveyed nearly 1,800 people with IBD, of whom 13% were young adults 18 to 25. IBD includes Crohn’s disease and ulcerative colitis.

    Results showed that young adults were significantly more likely to experience insurance-mandated step therapy, in which patients are required to try a lower-cost medication first before they can get coverage for the drug their doctor prefers.

    About 35% of young adults had to go through step therapy to get their meds covered, compared with 27% of adults 26 and older and 20% of pediatric patients under 18.

    Young adults also were less sure about how to manage coverage issues with their insurer.

    More than one-third (35%) reported low confidence in knowing which questions to ask their insurance company, compared to 25% of caregivers of pediatric patients.

    Young adults were also more likely to need to hustle for cash to cover their IBD care expenses, the survey found.

    About 18% of young adults took on extra jobs or more work hours to cover health care or insurance costs for their IBD, compared with 11% of adults and caregivers of pediatric patients, the study found.

    “The research highlights a need for targeted educational resources, improved insurance navigation assistance and policy attention to mitigate the unique challenges faced by young adults with IBD,” lead researcher Dr. Ross Maltz said in a news release. He’s a pediatric gastroenterologist at Nationwide Children’s Hospital in Columbus, Ohio.

    SOURCES: Crohn’s & Colitis Foundation of America, news release, Jan. 6, 2026; Crohn’s & Colitis 360, Jan. 6, 2026

    Copyright © 2026 HealthDay. All rights reserved.

    [ad_2]

    HealthDay

    Source link

  • Some mosquitoes like it hot

    Some mosquitoes like it hot

    [ad_1]

    Newswise — Certain populations of mosquitoes are more heat tolerant and better equipped to survive heat waves than others, according to new research from Washington University in St. Louis.

    This is bad news in a world where vector-borne diseases are an increasingly global health concern. Most models that scientists use to estimate vector-borne disease risk currently assume that mosquito heat tolerances do not vary. As a result, these models may underestimate mosquitoes’ ability to spread diseases in a warming world.

    Researchers led by Katie M. Westby, a senior scientist at Tyson Research Center, Washington University’s environmental field station, conducted a new study that measured the critical thermal maximum (CTmax), an organism’s upper thermal tolerance limit, of eight populations of the globally invasive tiger mosquito, Aedes albopictus. The tiger mosquito is a known vector for many viruses including West Nile, chikungunya and dengue.

    “We found significant differences across populations for both adults and larvae, and these differences were more pronounced for adults,” Westby said. The new study is published Jan. 8 in Frontiers in Ecology and Evolution.

    Westby’s team sampled mosquitoes from eight different populations spanning four climate zones across the eastern United States, including mosquitoes from locations in New Orleans; St. Augustine, Fla.; Huntsville, Ala.; Stillwater, Okla.; St. Louis; Urbana, Ill.; College Park, Md.; and Allegheny County, Pa.

    The scientists collected eggs in the wild and raised larvae from the different geographic locations to adult stages in the lab, tending the mosquito populations separately as they continued to breed and grow. The scientists then used adults and larvae from subsequent generations of these captive-raised mosquitoes in trials to determine CTmax values, ramping up air and water temperatures at a rate of 1 degree Celsius per minute using established research protocols.

    The team then tested the relationship between climatic variables measured near each population source and the CTmax of adults and larvae. The scientists found significant differences among the mosquito populations.

    The differences did not appear to follow a simple latitudinal or temperature-dependent pattern, but there were some important trends. Mosquito populations from locations with higher precipitation had higher CTmax values. Overall, the results reveal that mean and maximum seasonal temperatures, relative humidity and annual precipitation may all be important climatic factors in determining CTmax.

    “Larvae had significantly higher thermal limits than adults, and this likely results from different selection pressures for terrestrial adults and aquatic larvae,” said Benjamin Orlinick, first author of the paper and a former undergraduate research fellow at Tyson Research Center. “It appears that adult Ae. albopictus are experiencing temperatures closer to their CTmax than larvae, possibly explaining why there are more differences among adult populations.”

    “The overall trend is for increased heat tolerance with increasing precipitation,” Westby said. “It could be that wetter climates allow mosquitoes to endure hotter temperatures due to decreases in desiccation, as humidity and temperature are known to interact and influence mosquito survival.”

    Little is known about how different vector populations, like those of this kind of mosquito, are adapted to their local climate, nor the potential for vectors to adapt to a rapidly changing climate. This study is one of the few to consider the upper limits of survivability in high temperatures — akin to heat waves — as opposed to the limits imposed by cold winters.

    “Standing genetic variation in heat tolerance is necessary for organisms to adapt to higher temperatures,” Westby said. “That’s why it was important for us to experimentally determine if this mosquito exhibits variation before we can begin to test how, or if, it will adapt to a warmer world.”

    Future research in the lab aims to determine the upper limits that mosquitoes will seek out hosts for blood meals in the field, where they spend the hottest parts of the day when temperatures get above those thresholds, and if they are already adapting to higher temperatures. “Determining this is key to understanding how climate change will impact disease transmission in the real world,” Westby said. “Mosquitoes in the wild experience fluctuating daily temperatures and humidity that we cannot fully replicate in the lab.”

    [ad_2]

    Washington University in St. Louis

    Source link

  • Hypnosis Could Work Wonders on IBS

    Hypnosis Could Work Wonders on IBS

    [ad_1]

    The change in Zack Rogers was sudden. In the middle of his 12th birthday party, his stomach started hurting. He went to bed early that night, missing much of his own slumber party, and then stayed home from school the whole next week. The stomach pain was excruciating, and he couldn’t keep any food down. He lost 40 pounds in just a few weeks.

    Zack spent the next three years in and out of hospitals and trying medicines that didn’t seem to work. His doctors eventually told the family that they had only one option: surgery to remove large parts of his damaged colon. But Zack’s mom, Angela Rogers, wasn’t on board. She had lost faith in his medical team and feared such an invasive step, so she asked another gastroenterologist for a second opinion. The new doctor suggested that Zack try one last treatment before surgery: hypnotherapy, in which a clinical professional helps a patient become deeply focused and relaxed in order to change their patterns of thinking.

    This time, the change was gradual, but no less dramatic. In the evening after his first hypnotherapy session, Zack felt nauseated but kept his dinner down. Over the next few weeks, he stopped throwing up in school and regained the stamina to play basketball and go for bike rides. Today, Zack is a freshman in college, living away from home—something he wouldn’t have thought was possible before he was hypnotized. “If I never did hypnosis,” he told me, “I would be a complete mess. I genuinely don’t know where I would be.”

    As far-fetched as it may seem, science supports the idea that digestive disorders can be treated with psychological interventions, including hypnosis. Research dating back to the 1980s suggests that, at least in the short term, hypnotherapy can be an effective treatment for irritable bowel syndrome, a gut disorder characterized by painful gastrointestinal symptoms but no visible damage to the gut. Now scientists are investigating whether it might also bring relief to patients with inflammatory bowel disease, who, like Zack, have observable damage to their digestive tract.

    Although hypnosis is a powerful relaxation tool on its own, in clinical settings, it’s most often combined with other, better-studied psychotherapy techniques, such as cognitive behavioral therapy. Research suggests that CBT, which is commonly used to treat conditions such as depression and anxiety, can also be helpful in the treatment of gastrointestinal disorders.

    Unlike CBT, hypnosis retains a reputation for quackery, and is regularly portrayed in pop culture and stage shows as a tool for exercising control over participants—willing or otherwise. And some practitioners do use it for debunked treatments, including recovered memory therapy. But whether hypnotherapy is legitimized as a medical tool has real stakes. Hypnosis practitioners believe—and there’s some research to back this up—that the technique may amplify the effectiveness of more well-established psychological interventions and therefore has the potential to provide rare benefit to patients

    Hypnosis has a long history as a pain reliever. In the first half of the 19th century, before anesthetics were widely available, some surgeons hypnotized their patients. Even today, hypnosis proponents claim that it may be an effective alternative treatment for chronic back pain and the stress of childbirth; a growing body of research suggests that hypnosis can be a cost-effective and side-effect free analgesic for some people with chronic pain, though good clinical data are hard to come by.

    The first randomized controlled trial of hypnotherapy for IBS was published in 1984. Among the participants—a small group of mostly female patients with severe, treatment-resistant disease— those who received hypnotherapy showed greater improvements in abdominal pain, bloating, and bowel function than those who received psychotherapy plus a placebo medication. A 2014 meta-analysis found that about half of IBS patients who try hypnotherapy see at least short-term improvements in their symptoms.

    The evidence for hypnotherapy isn’t as robust in the treatment of IBD, which is really an umbrella term for ulcerative colitis (Zack’s diagnosis) and Crohn’s disease. But there’s reason to believe that hypnosis could yield similar success in addressing symptoms of those conditions. The line between IBD and IBS can be murky; more than a quarter of IBD patients in remission have IBS as well. And although the evidence is still mixed—a study published in 2021, for example, found no difference in treatment outcomes between standard medical treatments and hypnotherapy—some early evidence suggests that hypnotherapy can also reduce inflammation in patients with ulcerative colitis. One small study found that just one session of hypnotherapy reduced ulcerative-colitis patients’ blood levels of several inflammatory markers.

    Perhaps most important, a large body of research shows a strong link between cognition and digestion. Millions of neurons, collectively known as the enteric nervous system, regulate our digestion and are in constant communication with the central nervous system. This connection, called the “brain-gut axis,” may be why we feel so many emotions in our gut, whether the butterflies of anxiety or the clench of anger. It might also explain why both anxiety and depression are more common among patients with IBD compared with the general population. “Unequivocally, stress plays a major role in any digestive disease,” Gary Lichtenstein, a gastroenterology professor and the director of the Inflammatory Bowel Disease Center at the Hospital of the University of Pennsylvania, told me.

    When this brain-gut axis gets out of whack, it’s known to worsen some digestive disorders. In patients with gastrointestinal issues, the tissues in the gut can become hypersensitive over time. The brain learns to interpret signals from the gut, including normal functioning, as discomfort. This faulty communication results in what experts now call disorders of gut-brain interaction (DGBIs), which include IBS, functional dyspepsia, and other digestive disorders (but not IBD). Hypnosis, proponents say, can help patients rewire the cognitive-digestive connection. In many IBS and IBD cases, “we know there’s a mind-gut connection that can only be helped by a mental-health expert,” says Mark Mattar, a gastroenterologist and director of the IBD center at MedStar Georgetown University Hospital.

    Mattar works closely with Ali Navidi, the clinical psychologist to whom Zack was referred in 2020. Navidi told me that at his practice, GI Psychology, 83 percent of patients with DGBIs who complete at least 10 hypnotherapy sessions achieve their treatment goals, which usually amount to reducing pain, bloating, and other uncomfortable symptoms enough to go about their day-to-day life. His data are unpublished but in line with other studies on IBS showing that more than 80 percent of patients who get gut-directed hypnotherapy as part of their treatment plan experience improvements in pain and other GI symptoms. Those numbers are even higher among children and adolescents.

    Such findings persuaded the American College of Gastroenterology to recommend gut-directed psychotherapies—including hypnosis and CBT—for the treatment of IBS symptoms in its 2021 guidelines. Still, even among IBS patients, they’re not commonly used. No one appears to have studied the popularity of hypnosis specifically among IBS patients, but a 2017 study found that only 15 percent of people diagnosed with IBS had ever pursued “psychological therapies” of any kind.

    For many patients who follow through with hypnotherapy, the experience is not what they expect. Patients may conflate clinical hypnosis with entertainment hypnosis, where subjects quack like a duck or forget their own name. But at practices like Navidi’s, the therapist instead focuses on helping the patient enter a trance state—the same type of consciousness we all experience when we lose track of time working, scrolling Instagram, or driving and suddenly arriving at our destination. “When we’re in a trance, we have this intense, focused concentration, and that can be used in powerful ways,” Navidi said.

    Once the patient is in a trance state, therapists use guided imagery and suggestion to target specific gastrointestinal symptoms. “People get into a very relaxed state, and in that state I start to make suggestions about how the brain and the gut can work together better,” Jessica Gerson, a psychologist at NYU Langone’s Inflammatory Bowel Disease Center, told me. Gerson instructs her IBD patients to imagine the lining of their intestines healing. During his trance states, Zack was able to envision a control room for his pain in which he could dial knobs up and down. “I could turn the stomach pain down to a one or a zero, and it would go away,” Zack recalled recently, a note of surprise still in his voice.

    Many patients initially fear that during hypnosis they are ceding control of their mind and body to the hypnotherapist, Gerson told me. But patients are always “totally conscious, totally in control.” Indeed, Navidi and Gerson use this trance state to show patients exactly how much control they have over their own body. “Having a sense of agency is therapeutic,” Gerson said.

    These days, many gastroenterologists see psychotherapies like hypnosis as an important part of a holistic treatment plan—even for IBD. (IBD patients who do respond to hypnotherapy are likely to continue to need medical monitoring and interventions, Lichtenstein said.) While gut-directed hypnotherapy still hasn’t been proved to help IBD patients without co-occurring IBS symptoms, there’s not much of a downside to trying. The experts I spoke with agreed that hypnosis is relatively risk-free as long as it is administered by a clinician, patients continue to be monitored by their medical doctors, and therapists screen potential patients for severe mental illness and untreated trauma. Patients, too, need to consider whether they can afford hypnotherapy. Like many mental-health services, it’s not always covered by insurance. Zack’s sessions were $265 each out of pocket, but according to Angela, “it was worth every cent and then some.”

    Zack remembers getting stressed out a lot as a kid—over grades, making friends, basketball games, or nothing in particular. He credits Navidi with alleviating not only his stomach pain but also the relentless anxiety; he still uses the relaxation techniques he learned from Navidi when he gets worried about school or a basketball game.

    Zack is still on medication for his ulcerative colitis; every eight weeks he has an injection of Stelara, a medication that works by blocking inflammatory proteins. But after two years of appointments with Navidi, for the first time since his 12th birthday, his symptoms are reliably under control—and stress doesn’t make them come roaring back. He hasn’t had a flare up in about a year and a half. Most days, he doesn’t think about his diagnosis at all.

    [ad_2]

    Kate Wheeling

    Source link

  • The Threat of Cholera in Africa

    The Threat of Cholera in Africa

    [ad_1]

    Newswise — Announcing a new article publication for Zoonoses journal. A multi-country cholera outbreak has occurred in several developing countries in Africa, Asia and Oceania since mid-2021. The current multi-country cholera outbreak has spread primarily in Africa. As of February 2023, cholera cases have been reported in approximately 25 countries, 15 (60%) of which are in sub-Saharan Africa.
    According to the World Health Organization, 547,626 confirmed cases and 4,927 total deaths were recorded until August 2023. Of these, approximately 33.68% cases (184,474) and 64.2% deaths (3,165) occurred in African countries, and the number may increase in the coming months. Although various organizations and local administrations have made response efforts, the response capacity for multiple outbreaks is insufficient, and the outbreak has been exacerbated by a global lack of resources, cholera vaccine shortages, climatic effects, a lack of supplies and the occurrence of other health emergencies.
    This review article provides current alert information regarding the broad spread and upsurge characteristics of the ongoing cholera outbreak.
    # # # # # #

    [ad_2]

    Compuscript Ltd

    Source link

  • AI can predict certain forms of esophageal and stomach cancer

    AI can predict certain forms of esophageal and stomach cancer

    [ad_1]

    BYLINE: Jina Sawani, Michigan Medicine

    Newswise — In the United States and other western countries, a form of esophageal and stomach cancer has risen dramatically over the last five decades. Rates of esophageal adenocarcinoma, or EAC, and gastric cardia adenocarcinoma, or GCA, are both highly fatal.

    However, Joel Rubenstein, M.D., M.S., a research scientist at the Lieutenant Colonel Charles S. Kettles Veterans Affairs Center for Clinical Management Research and professor of internal medicine at Michigan Medicine, says that preventative measures can be a saving grace.

    “Screening can identify pre-cancerous changes in patients, Barrett’s esophagus, which is sometimes diagnosed in individuals who have long-term gastroesophageal reflux disease, or GERD,” he said.

    “When early detection occurs, patients can take additional steps to help prevent cancer.”

    While current guidelines already consider screening in high-risk patients, Rubenstein notes that many providers are still unfamiliar with this recommendation.

    “Many individuals who develop these types of cancer never had screening to begin with,” he said.

    “But a new automated tool embedded in the electronic health record holds the potential to bridge the gap between provider awareness and patients who are at an increased risk of developing esophageal adenocarcinoma and gastric cardia adenocarcinoma.”

    Rubenstein and a team of researchers used a type of artificial intelligence to examine data regarding EAC and GCA rates in over 10 million U.S. veterans.

    Their findings were published in Gastroenterology

    Rubenstein and his team developed and tested the Kettles Esophageal and Cardia Adenocarcinoma predictioN tool, called K-ECAN for short.

    “K-ECAN uses basic information already readily available in the EHR, like patient demographics, weight, previous diagnoses and routine laboratory results, to determine an individual’s risk of developing esophageal adenocarcinoma and gastric cardia adenocarcinoma,” said Rubenstein.

    “We developed a prior tool, M-BERET, over a decade ago for identifying patients with Barrett’s esophagus. However, that tool requires measuring patients’ hip and waist circumferences, which is not something that routinely occurs. In addition, providers must remember to use the corresponding website to calculate their patient’s risk when using this tool.”

    To alleviate this burden, Rubenstein said that they “envisioned harnessing the large amount of data already present in the EHR, as well as presenting their patients’ risk to their providers at opportune times,” such as when an individual is due for a colorectal screening or refilling an acid reducing prescription medication.

    According to Rubenstein, K-ECAN is more accurate than published guidelines or previously validated prediction tools and can “accurately predict cancer at least three years prior to a diagnosis.”

    “Symptoms of GERD, like heartburn, are an important risk factor for esophageal adenocarcinoma,” he said.

    “But most people with GERD symptoms will never develop esophageal adenocarcinoma and gastric cardia adenocarcinoma. In addition, roughly half of the patients with this form of cancer never experienced prior GERD symptoms at all. This makes K-ECAN particularly useful because it can identify people who are at elevated risk, regardless of whether they have GERD symptoms or not.”

    Akbar Waljee, M.D., M.Sc., professor in the Departments of Learning Health Sciences and Internal Medicine and senior author on the study, adds that this research wouldn’t be possible without a collaborative effort.

    “This publication, which leveraged invaluable data from millions of U.S. veterans, was made possible through the dedicated efforts of numerous staff members at our VA Health Services Research & Development Center of Innovation, as well as through collaborative partnerships between the VA Center for Clinical Management Research, Michigan Medicine, the University of Michigan Department of Statistics, and members of U-M’s Institute for Healthcare Policy & Innovation and E-Health & Artificial Intelligence, or e-HAIL. This exemplifies the power of team science, data and machine learning to improve cancer prevention.”

    Incorporating this artificial intelligence tool into the EHR could alert providers with an automated notification regarding which patients are at an increased risk of developing esophageal adenocarcinoma and gastric cardia adenocarcinoma.

    And Rubenstein says that this can significantly decrease the burden of these cancers

    “Our devoted team was able to use sophisticated machine learning tools to develop this unique tool, and we are very excited that this could potentially lead to increased screening and a decrease in preventable deaths. We look forward to conducting additional work validating K-ECAN for use outside of the VA.”

    [ad_2]

    Michigan Medicine – University of Michigan

    Source link

  • New study will compare microbes on fresh produce from gardens versus supermarkets

    New study will compare microbes on fresh produce from gardens versus supermarkets

    [ad_1]

    BYLINE: Laurel Hamers, University Communications

    Newswise — EUGENE, Ore. – August 21, 2023 — The journey that your fruits and veggies take to get to your plate might affect the beneficial microbes they bring you.

    New University of Oregon research will investigate how microbes found on produce affect the gut microbiome, and compare how those microbes differ between produce from a home garden versus those from the supermarket.

    The project is led by Gwynne Mhuireach, a research assistant professor in the Institute for Health in the Built Environment. Her pilot study is supported by a grant from the United States Department of Agriculture.

    We take in millions of microbes every day via the food we eat. While some microbes can cause disease, many others are beneficial—and even necessary—for health.

    “The veggies you get in the supermarket have been through so much on their supply chain processing,” Mhuireach said. Previous studies suggest that they’ve lost most of the microbes they started with by the time they reach a consumer’s kitchen. “But then they also have new microbes from being handled and being in storage.”

    Produce from a backyard garden or a community garden is also filled with microbes but its journey from plant to plate is much shorter, and the environment in which it’s grown is different too. These fruits and vegetables are more likely to be surrounded by a variety of other plants, for example, rather than grown in vast monoculture fields.

    “I want to see if there’s a vast difference, microbiologically speaking, between garden and supermarket veggies,” Mhuireach said. And she wants to see whether those microbial differences can in turn impact people’s gut microbiomes.

    Each participant will spend a week eating produce only from their own garden or a community garden, and another week eating a similar meal plan but with only supermarket produce. They’ll collect daily fecal samples, which Mhuireach and her team will submit for genetic sequencing to identify the microbes within. That will allow the researchers to track how the gut microbiome is changing over time in response to different diets.

    Depending on the preliminary results, Mhuireach hopes to expand to a larger sample. Her team is currently recruiting participants for the study. Interested participants can learn more about the study and find a link to the eligibility screening survey here: https://gffstudy.com/

    This research is supported by the United States Department of Agriculture.

    About the College of Design The University of Oregon’s College of Design is home to creative practitioners, social scientists, biologists, and planners. It offers numerous undergraduate degrees and graduate accredited degrees, independent centers and institutes, and a myriad of minors and certificates at its Eugene and Portland campuses. The college is comprised of the Department of the History of Art and Architecture, School of Architecture & Environment, School of Art + Design, and School of Planning, Public Policy and Management. 

    [ad_2]

    University of Oregon

    Source link

  • COVID quelled GI viruses, but resurgence after 2 years

    COVID quelled GI viruses, but resurgence after 2 years

    [ad_1]

    Newswise — Washington, D.C. –  Following the first stay-at-home orders issued in the U.S. to curb the spread of COVID-19, gastrointestinal viruses such as norovirus, rotavirus and adenovirus all but disappeared from California communities, and remained at very low levels for nearly 2 years. The research is published in the Journal of Clinical Microbiology, a journal of the American Society for Microbiology.

    Interestingly, these viruses surged back to pre-pandemic levels in late 2022, said Niaz Banaei, M.D., professor of Pathology and Medicine (Infectious Diseases), Stanford University, and Medical Director of Clinical Microbiology Laboratory, Stanford Health Care. “Adenovirus F40/41, the adenovirus strains most frequently associated with gastroenteritis, actually jumped to levels two-fold higher than pre-pandemic levels.” 

    Banaei suspects that the surge in viral infections was enabled by the waning of collective community immunity from lack of exposure during the pandemic. “Something similar has been described for the surge in respiratory syncytial virus infections in 2022,” he said. 

    To identify changes in the prevalence of gastrointestinal pathogens, the investigators compared detection rates for community acquired gastrointestinal pathogens before, during and after California’s COVID-related shelter-in-place. To that end, they used a polymerase chain reaction (PCR) panel test called the BioFire FilmArray GI panel, which tests for 22 of the most common pathogens that cause diarrhea and analyzed about 18,000 tests that were taken from January 2018 to December 2022. 

    The motivation for the research was the change in the rate of positives for certain pathogens during the COVID-19 pandemic, said Banaei. “It immediately became clear that the pandemic lockdown and shelter-in-place had created a natural experiment to investigate the transmission dynamics of pathogens causing gastroenteritis.” 

    The research offers a unique window into the biology of gastrointestinal pathogens, raising some new research questions, said Banaei. “Why did some disappear while others persisted unaffected during lockdown? Why are some now surging to levels we haven’t seen before?” Improved understanding of these phenomena could lead to ways to interrupt pathogens’ spread, particularly in low- to middle-income countries where gastroenteritis remains a major cause of illness and death, especially among children. “It may also help us prepare for future unforeseen pandemics.”

    [ad_2]

    American Society for Microbiology (ASM)

    Source link

  • NCCN Announces Research Funding for Biomarker-Directed Therapy in Metastatic Colorectal Cancer, in Collaboration with Fight CRC and Pfizer

    NCCN Announces Research Funding for Biomarker-Directed Therapy in Metastatic Colorectal Cancer, in Collaboration with Fight CRC and Pfizer

    [ad_1]

    Newswise — PLYMOUTH MEETING, PA [August 9, 2023] — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced new grants awarded to improve quality initiatives focused on optimizing biomarker-directed therapy in metastatic colorectal cancer. Fight Colorectal Cancer (Fight CRC) collaborated with NCCN and Pfizer, Inc in the grant process; Pfizer will provide funding and oversee the projects. 

    Metastatic colorectal cancer (mCRC) is a complex, heterogeneous disease characterized by multiple gene alterations that can significantly impact a patient’s prognosis and treatment option profile. Biomarker testing has transformed the landscape of mCRC care and is critical to ensuring a patient receives appropriate, evidence-based care. The goal of this project is to optimize biomarker-directed therapy based on established clinical practice guidelines in mCRC.

    “Biomarker testing to determine optimal therapy in metastatic colorectal cancer can be complex, cumbersome, and prolonged, which leads to delays in appropriate patient care. These barriers exist throughout the biomarker testing continuum and include provider ordering, patient education, insurance coverage, tissue acquisition, data interpretation, and treatment implications” explained Crystal S. Denlinger, MD, FACP, Senior Vice President, Chief Scientific Officer, NCCN. “These investigators will hopefully provide research that leads to improving a key component of delivering guideline-concordant care.”

    The selected projects are:

    • Stacey A. Cohen, MD, Fred Hutchinson Cancer Center
      • Implementation of a Rapid Assessment of Molecular Profiling of Metastatic Colorectal Cancer by Liquid Biopsy in Multi-Institutional Setting
    • Amit Mahipal, MD, MPH and Melissa Lumish, MD, Case Comprehensive Cancer Center and University Hospitals Seidman Cancer Center
      • Biomarker-driven and Evidence-Based Therapy for metastatic ColoRectal Cancer (BEAT-CRC): A System-Wide Initiative to Increase Access to Biomarker-Driven Therapy in a Large Practice
    • Vanessa Wookey, MD, Fox Chase Cancer Center
      • Improving Biomarker Testing in Patients with Metastatic Colorectal Cancer through Patient Education

    “At Pfizer, we’re committed to raising awareness of both the importance of biomarker testing in mCRC as well as optimizing clinical implementation,” said Faisal Mehmud, MD, Precision Medicine & Early Pipeline Lead at Pfizer. “Improving access to biomarker testing as well as increasing our knowledge about testing methods are key to help improve outcomes for patients living with this type of devastating cancer. We are excited to partner with NCCN and Fight CRC on this project and are pleased to support three outstanding projects that have the potential to make a significant contribution in this important initiative.”

    “Envisioning a future where metastatic colorectal cancer patients receive optimal and personalized treatment without unnecessary hurdles is at the heart of Fight CRC’s mission,” stated Anjee Davis, MPPA, President of Fight Colorectal Cancer (Fight CRC). “In partnership with Pfizer and NCCN, we are thrilled to reveal these transformative grants designed to dismantle barriers throughout the biomarker testing journey. Through a proactive approach in addressing patients’ challenges and expanding access to biomarker testing, we forge a path towards conquering this complex disease, all while empowering patients to become their own advocates in their fight for better outcomes.”

    Proposals were peer reviewed by a Scientific Review Committee, which consisted of leading expert oncologists from NCCN Member Institutions. The selected projects are set to be completed within two years. Nearly $750,000 in funding will be provided across all grants.

    The NCCN ORP fosters innovation and knowledge discovery that improve the lives of people with cancer and supports preclinical, translational, clinical research, and quality improvement projects in oncology at NCCN Member Institutions. In an effort to improve collaboration in cancer research, the NCCN ORP also maintains a shared resources website, an informed consent database, and points to consider on the best practices for biorepositories, registries, and databases. For more information, visit NCCN.org/orp.

    # # #

    About the National Comprehensive Cancer Network

    The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) provide transparent, evidence-based, expert consensus recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit NCCN.org for more information.

    [ad_2]

    National Comprehensive Cancer Network(r) (NCCN(r))

    Source link

  • In-Depth Colonoscopy Analysis: New Deep-Learning Approach Unveiled

    In-Depth Colonoscopy Analysis: New Deep-Learning Approach Unveiled

    [ad_1]

    Newswise — Researchers have developed a pair of modules that gives a boost to the use of artificial neural networks to identify potentially cancerous growths in colonoscopy imagery, traditionally plagued by image noise resulting from the colonoscopy insertion and rotation process itself.

    A paper describing the approach was published in the journal CAAI Artificial Intelligence Research on June 30.

    Colonoscopy is the gold standard for detecting colorectal growths or ‘polyps’ in the inner lining of your colon, also known as the large intestine. Via analysis of the images captured by a colonoscopy camera, medical professionals can identify polyps early on before they spread and cause rectal cancer. The identification process involves what is called ‘polyp segmentation,’ or differentiating the segments within an image that belong to a polyp from those segments of the image that are normal layers of mucous membrane, tissue and muscle in the colon.

    Humans traditionally performed the whole of the image analysis, but in recent years, the task of polyp segmentation has become the purview of computer algorithms that perform pixel-by-pixel labelling of what appears in the image. To do this, computational models mainly rely on characteristics of the colon and polyps such as texture and geometry.

    “These algorithms have been a great aid to medical professionals, but it is still challenging for them to locate the boundaries of polyps,” said Bo Dong, a computer scientist with the College of Computer Science at Nankai University and lead author of the paper. “Polyp segmentation needed an assist from artificial intelligence.”

    With the application of deep learning in recent years, polyp segmentation has achieved great progress over cruder traditional methods. But even here, there remain two main challenges.

    First, there is a great deal of image ‘noise’ that polyp segmentation deep learning efforts struggle with. When capturing images, the colonoscope lens rotates within the intestinal tract to capture polyp images from various angles. This rotational movement often leads to motion blur and reflection issues. This complicates the segmentation task by obscuring the boundaries of the polyps.

    The second challenge comes from the inherent camouflage of polyps. The color and texture of polyps often closely resemble that of the surrounding tissues, resulting in low contrast and strong camouflage. This similarity makes it difficult to distinguish polyps from the background tissue accurately. The lack of distinctive features hampers the identification process and adds complexity to the segmentation task.

    To address these challenges, the researchers developed two deep learning modules. The first, a “Similarity Aggregation Module,” or SAM, tackles the rotational noise issues, and the second, Camouflage Identification Module, or CIM, addresses camouflage.

    The SAM extracts information from both individual pixels in an image, and via “semantic cues” given by the image as a whole. In computer vision, it is important not merely to identify what objects are in an image, but also the relationships between objects. For example, if in a picture of a street, there is a red, three-foot high, cylindrical object on a sidewalk next to the road, the relationships between that red cylinder and both the sidewalk and road give the viewer additional information beyond the object itself that aid in identification of the object as a fire hydrant. Those relationships are semantic cues. They can be represented as a series of labels that are used to assign a category to each pixel or region of pixels in an image.

    The novelty of the SAM however is that it extracts both local pixel information and these more global semantic cues via use of non-local and graph convolutional layers. Graph convolutional layers in this case consider the mathematical structure of relationships between all parts of an image, and non-local layers are a type of node in a neural network that assesses more long-range relationships between different parts of an image.

    The SAM enabled the researchers to achieve a 2.6 percent increase in performance compared to other state-of-the-art polyp segmentation models when tested on five different colonoscopy image datasets widely used for deep learning training.

    To overcome the camouflage difficulties, the CIM captures subtle polyp clues that are often concealed within low-level image features—the fine-grained visual information that is present in an image, such as the edges, corners, and textures of an object. However, in the context of polyp segmentation, low-level features can also include noise, artifacts, and other irrelevant information that can interfere with accurate segmentation. The CIM is able to identify the low-level information that is not relevant to the segmentation task, and filters it out. With the integration of the CIM, the researchers were able to achieve an additional 1.8% improvement compared to other state-of-the-art polyp segmentation models.

    The researchers now want to refine and optimize their approach to reduce its significant computational demand. By implementing a range of techniques including model compression, they hope to reduce the computational complexity sufficient for application in real-world medical contexts.

     

    ###

    [ad_2]

    Tsinghua University Press

    Source link

  • Transcription Factors Contribute to Subtypes of Colorectal Cancers

    Transcription Factors Contribute to Subtypes of Colorectal Cancers

    [ad_1]

    Newswise — New research in colorectal cancers directed by investigators at the Johns Hopkins Kimmel Cancer Center suggests that expression of transcription factors — proteins that help turn specific genes on or off by binding to nearby DNA — may play a central role in the degree of DNA methylation across the genome, contributing to the development of different subtypes of these cancers. Methylation is a process in which certain chemical groups attach to areas of DNA that guide genes’ on/off switches. Studying the expression of these transcription factors in patients with colorectal cancers could reveal biomarkers to help determine overall survival in people with a subgroup of colorectal cancers who generally have better survival rates and, importantly, respond better to immune checkpoint therapy — a type of immunotherapy that releases restraints that cancer cells place on the immune response — and other treatments. Similar patterns of transcription factor expression could be seen by the researchers even in precancerous polyps, and could potentially be used by physicians to determine which patients need closer follow-up to prevent cancer development.

    A description of the work was published online July 24 in the journal Proceedings of the National Academy of Sciences.

    Aberrant DNA methylation is a well-known phenomenon occurring in cancers, explains senior study author Hariharan Easwaran, Ph.D., M.Sc., an associate professor of oncology at the Johns Hopkins Kimmel Cancer Center, but the degree of DNA methylation varies in cancers of the same tissue type. Some colon and other cancers have a very high degree of DNA methylation gains while others have much lower frequency of DNA methylation gains, he says. Traditionally, these have been described in an area of the genome known as a promoter region, which helps launch the transcription process. The exact mechanisms underlying these changes have not been clear.

    In a series of laboratory studies of genetic material taken from tubular adenomas (precancerous polyps in the colon) and colon tumors, the researchers linked cancer-specific transcription factor expression alterations to methylation alterations in colorectal cancers and their premalignant precursor lesions, which provided insights into the origins and evolution of different molecular subtypes of colorectal cancers.

    Specifically, researchers observed that some regions of the genome undergoing increased methylation tend to have binding sites for transcription factors that are downregulated, or have low expression. In some types of colon cancer, based on the types of genetic alterations associated with the cancer, transcription factors are upregulated or have higher expression.

    The findings suggest that cancer-specific methylation differences potentially evolve due to perturbation in the activity or expression of transcription factors. Similar changes in DNA methylation patterns were observed in precancerous polyps.

    “These studies highlight that the transcription factor expression changes and corresponding DNA methylation changes are early events during tumor development,” says lead study author Yuba Bhandari, Ph.D., a research associate at the Johns Hopkins Kimmel Cancer Center. “As polyps do not carry all of the key genetic changes typically found in full-blown cancer cells, the transcription factor changes may represent the earliest molecular regulators of precancerous cells, with profound impact on the genome-wide DNA methylation changes.”

    The specific set of transcription factors identified in the study may help in stratifying colorectal cancer prognosis, Easwaran adds.

    “This is particularly important, because multiple studies have shown that a certain subtype of colorectal cancers responds best to immune checkpoint blockade therapies, while others may not fare as well,” he says. “Expression profiling of relevant transcription factors may help develop better therapeutic strategies across subtypes of colorectal cancers.”

    Additional study co-authors included Rachael Powers, Sehej Parmar, Sara-Jayne Thursby, Ekta Gupta, Ozlem Kulak, Kurtis Bachman and Stephen Baylin of Johns Hopkins. Additional investigators from Janssen Research and Development in Pennsylvania and in Belgium contributed.

    The work was supported by the National Institutes of Health grants R01CA230995 and R01CA229240; National Institute of Environmental Health Sciences grant R01ES011858; National Cancer Institute grant R21CA212495; Sam Waxman Research Foundation and National Institute on Aging grant U01AG066101; Janssen Initiative; Commonwealth Grant; and Grollman Glick Scholarship.

    Baylin consults for MDxHealth. Methylation-specific PCR is licensed to MDxHealth in agreement with The Johns Hopkins University. Baylin and JHU are entitled to royalty shares received from sales. These arrangements have been reviewed and approved by The Johns Hopkins University in accordance with its conflict-of-interest policies.

    [ad_2]

    Johns Hopkins Medicine

    Source link

  • أظهرت جراحة طفيفة التوغل لتحديد مرحلة سرطان البنكرياس نتائج إيجابية في تحديد سير المرض، وذلك وفقًا لدراسة أجرتها مايو كلينك.

    أظهرت جراحة طفيفة التوغل لتحديد مرحلة سرطان البنكرياس نتائج إيجابية في تحديد سير المرض، وذلك وفقًا لدراسة أجرتها مايو كلينك.

    [ad_1]

    Newswise — روتشستر، مينيسوتا— أظهرت دراسة نُشرت في مجلة الكلية الأمريكية للجراحين أن إجراء جراحة بسيطة للمرضى الذين شُخصت إصابتهم حديثًا بمرض سرطان البنكرياس قد يساعد في تحديد مدى انتشار السرطان مبكرًا ومعرفة مرحلته. وأضاف الباحثون أنه يفضل أن تُجرى هذه الجراحة قبل أن يبدأ المريض العلاج الكيميائي.

    يقول مارك تورتي، دكتور في الطب، اختصاصي جراحة الأورام في مركز مايو كلينك الشامل لعلاج السرطان، ورائد هذا البحث: “هذه دراسة مهمة لأنها تدعم أسلوب تحديد مرحلة المرض باستخدام التنظير البطني للمساعدة في تحديد سير المرض ومعرفة العلاج المناسب حتى يتفادى المرضى العلاج الجراحي غير الفعّال أو الذي يحتمل أن يكون ضارًا.” وأضاف: “إن نسبة النجاة من سرطان البنكرياس ضئيلة للغاية مقارنةً بأنواع السرطان الأخرى، كما أنه ينتشر بسرعة. لذلك فإن الحصول على هذه المعلومات في حالة انتشار السرطان سيفيد المرضى ويساعد الأطباء على تحديد العلاج الصحيح للمريض في أسرع وقت ممكن.”

    يُسمى العلاج الجراحي طفيف التوغل التنظير البطني المرحلي حيث يُدخل الجراح مصدر ضوئي وكاميرا (منظار بطني) إلى داخل البطن عبر شقوق رفيعة وصغيرة ليرى ما إذا كان السرطان قد انتشر داخل التجويف البطني. وقد يدمج الطبيب مع هذا الإجراء الغسيل البريتوني، حيث يُدخل سائل إلى داخل التجويف البطني ثم يخرجه ويفحصه تحت الميكروسكوب بحثًا عن خلايا سرطانية.

    خلال دراسة استمرت خمس سنوات، قام فريق الدراسة بتقييم بيانات أكثر من 1000 مريض، وأظهر البحث أن مريضًا واحدًا من كل 5 مرضى ممن خضعوا للتنظير البطني المرحلي لسرطان البنكرياس كان مصابًا بسرطان منتشر في الكبد أو بطانة البطن (الصفاق). 

    بالإضافة إلى ذلك، اكتشف الباحثون مجموعة متنوعة من العوامل التي تحدد المرضى الأكثر عرضة لانتشار السرطان. وشملت هذه العوامل عمر المريض وموضع الورم والواسمات الورمية (CA 19-9) في الدم. يقول الباحثون أنه كلما زادت عوامل الخطر الموجودة، زادت مخاطر انتشار السرطان.

    تقول هالبيرا جودموندسدوتير، دكتور في الطب، طبيبة جراحة عامة مقيمة، وباحثة في مركز روبرت د. وباتريشيا إي. كيرن لتقديم الرعاية الطبية في مايو كلينك: “نوصي، بناءً على هذه النتائج، أن يُجرى التنظير البطني المرحلي قبل بدء العلاج الكيميائي لأغلبية المرضى المصابين بسرطان البنكرياس والمرشحين للخضوع للجراحة.” يمكن أن تساعد نتائج التنظير البطني المرحلي في تحديد الخيار الأمثل لكل مريض، مثل الاستئصال الجراحي أو العلاج الكيميائي.

    ###

    نبذة عن مايو كلينك
    مايو كلينك هي مؤسسة غير ربحية تلتزم بالابتكار في الممارسات السريرية والتعليم والبحث وتوفير التعاطف والخبرة لكل مَن يحتاج إلى الاستشفاء والرد على استفساراته. لمعرفة المزيد من أخبار مايو كلينك، تفضَّل بزيارة شبكة مايو كلينك الإخبارية.

    [ad_2]

    Mayo Clinic

    Source link

  • La determinación temprana de la etapa del cáncer de páncreas con cirugía de invasión mínima muestra resultados positivos en el pronóstico del paciente, según estudio de Mayo Clinic

    La determinación temprana de la etapa del cáncer de páncreas con cirugía de invasión mínima muestra resultados positivos en el pronóstico del paciente, según estudio de Mayo Clinic

    [ad_1]

    Newswise — ROCHESTER, Minnesota — Un estudio publicado en el Journal of the American College of Surgeons revela que realizar un procedimiento quirúrgico menor en pacientes con un diagnóstico reciente de cáncer de páncreas ayuda a identificar la diseminación temprana del cáncer y determinar la etapa del cáncer. Los investigadores agregan que lo ideal sería que la cirugía se realice antes de que el paciente comience la quimioterapia.

    “Es un estudio importante porque respalda el hecho de que la laparoscopia de estadificación puede ayudar a determinar el pronóstico de un paciente y brindar más información para el tratamiento con el fin de que los pacientes eviten un tratamiento quirúrgico inútil o potencialmente dañino”, dice el Dr. Mark Truty, oncólogo cirujano del Centro Oncológico Integral de Mayo Clinic, quien dirigió esta investigación. “El cáncer de páncreas es el más difícil de combatir de todos los tipos de cáncer y se disemina rápido. Por lo tanto, contar con la información de si el cáncer se ha diseminado beneficiará a los pacientes y ayudará a los médicos a determinar el tratamiento adecuado para el paciente lo antes posible”.

    El procedimiento quirúrgico de invasión mínima se denomina laparoscopia de estadificación y lo realiza un cirujano insertando una luz y una cámara (laparoscopio) en el abdomen a través de hendiduras pequeñas y delgadas para ver si el cáncer se ha diseminado dentro de la cavidad abdominal. El cirujano también puede combinarlo con lavados peritoneales, donde se inserta líquido en la cavidad abdominal y después se extrae y evalúa con un microscopio en busca de células cancerosas.

    Durante el estudio de cinco años, los autores evaluaron datos de más de 1000 pacientes, y la investigación mostró que 1 de 5 pacientes que se sometieron a una laparoscopia de estadificación para el cáncer de páncreas tenía cáncer que se había diseminado al hígado o al revestimiento del abdomen (peritoneo). 

    Además, los investigadores hallaron una variedad de factores que identificaron qué pacientes tenían más probabilidades de que el cáncer se diseminara. Estos factores incluían la edad del paciente, la ubicación del tumor y los marcadores tumorales (CA 19-9) en la sangre. Los investigadores sostienen que cuantos más factores de riesgo estén presentes, mayor será el riesgo de encontrar cáncer diseminado.

    “En función de estos resultados, recomendamos que la laparoscopia de estadificación se realice antes de comenzar la quimioterapia en la mayoría de los pacientes que padecen cáncer de páncreas y que se está considerando para cirugía”, destaca el primer autor, el Dr. Hallbera Gudmundsdottir, médico residente de cirugía general y académico del Centro Robert D. y Patricia E. Kern para la Ciencia de Brindar Atención Médica de Mayo Clinic. Los hallazgos sobre la laparoscopia de estatificación pueden orientar sobre qué tratamiento será la mejor opción para cada paciente, como la extirpación quirúrgica o la quimioterapia.

    ###

    Información sobre Mayo Clinic
    Mayo Clinic es una organización sin fines de lucro, dedicada a innovar la práctica clínica, la educación y la investigación, así como a ofrecer pericia, compasión y respuestas a todos los que necesitan recobrar la salud. Visite la Red Informativa de Mayo Clinic para leer más noticias sobre Mayo Clinic.

    [ad_2]

    Mayo Clinic

    Source link

  • New Method Simplifies Identification of Right Treatment for Tabooed Disease Affecting Thousands

    New Method Simplifies Identification of Right Treatment for Tabooed Disease Affecting Thousands

    [ad_1]

    Newswise — Most people have at some point in their life suffered an intestinal infection or food poisoning forcing them to stay close to the bathroom. It is very uncomfortable. Most of the time, though, it passes quickly.

    But around 60,000-100,000 Danes suffer from a form of chronic diarrhoea called bile acid malabsorption or bile acid diarrhoea.

    It is a chronic condition characterised by frequent and sudden diarrhoea more than 10 times a day. Even though the disease is not life-threatening, it can seriously affect the patient’s everyday life, especially their social life, and be extremely disabling.

    “You have to rush to the bathroom several times a day. Therefore, keeping a job or maintaining social relations can be difficult, and a lot of people isolate themselves. The disease controls their life,” says Professor Jesper Bøje Andersen from the Biotech Research & Innovation Centre.

    He and his research group and clinical cooperation partners at Herlev and Gentofte Hospital headed by Professor and Consultant Doctor Filip Krag Knop are responsible for a new study, which provides new ways of diagnosing bile acid diarrhoea and identifying the most effective treatment for the individual patient.

    “A lot of people with chronic diarrhoea don’t realise that they suffer from bile acid diarrhoea and what has caused it. This is a result of lack of knowledge among healthcare workers and the relatively complex and expensive – and for the patient difficult – process of diagnosing the disease,” says Filip Krag Knop.

    Jesper Bøje Andersen adds:

    “We have developed a new concept which may be used to diagnose the disease based on a simple blood sample. Today, diagnostics involves radiopharmaceuticals, which means that there is a radiation risk. The process is not necessarily dangerous, but unpleasant and arduous, and not all countries in the world support the method, including the US.”

    The new method means that doctors should be able to determine whether the patient has bile acid diarrhoea based on a simple blood sample. They focus on molecules known as metabolites in the blood.

    “A blood sample contains lots of different metabolites. Right now we are able to identify almost 1,300 different metabolites, and around a handful of these can be used to diagnose bile acid diarrhoea. The metabolites of bile acid diarrhoea patients form a particular pattern that makes them recognisable,” says Jesper Bøje Andersen.

    Which treatment?

    The researchers analysed blood samples from 50 patients and they quickly realised that the samples – and patients – could be divided into two groups.

    “First, we did not understand why. All the blood samples had been taken before treatment, typically at the time of diagnosis,” says Jesper Bøje Andersen.

    The patients then participated in a randomised clinical study at the Center for Clinical Metabolic Research at Herlev and Gentofte Hospital. Here the doctors studied the effect of two different treatments: the conventional treatment involving bile acid sequestrant colesevelam and a new treatment involving liraglutide, which is normally used to treat type 2 diabetes and severe overweight.

    “What is interesting is that the metabolites in the patients’ blood divided them into two groups: one that responds well to colesevelam and one that responds well to liraglutide. This suggests that we should be able to say which treatment is the most effective by analysing the patient’s blood at the time of diagnosis,” says Jesper Bøje Andersen.

    The clinical study showed that colesevelam treatment eased the bile acid diarrhoea symptoms of 50 per cent of the patients, while liraglutide treatment eased the symptoms of 77 per cent of the patients.

    Jesper Bøje Andersen, Filip Krag Knop and their research groups hope the new study will benefit the 60,000-100,000 Danes who suffer from bile acid diarrhoea.

    The majority of cases of bile acid diarrhoea is diagnosed at a very late stage or never diagnosed at all.

    “Around 40 per cent of the patients suffer from this condition for up to five years before it is diagnosed. Of course, this may be because they do not realise that it is a disease and that it can be treated. But it may also be because chronic diarrhoea is a tabooed disease,” says Filip Krag Knop.

    You can read the study, “The Serum Lipidome Unravels a Diagnostic Potential in Bile Acid Diarrhea”, in Lewinska & Kårhus et al., GUT.

     

    About bile acid diarrhoea

    When we eat high-fat food, the gallbladder releases bile acid. Bile acid helps the body absorb fat and fat-soluble vitamins from the food. Around 98 per cent of the bile acid is absorbed by the small intestine and returned via the blood to the liver. If the body either produces and/or releases excessive amounts of bile acid or if the bile acid is not reabsorbed by the blood, a large amount will end up in the large intestine. Here it will result in irritated mucosa, lack of fluid in the intestines and increased intestinal movements, all of which create symptoms of bile acid diarrhoea.

    [ad_2]

    University of Copenhagen, Faculty of Health and Medical Sciences

    Source link

  • Study: After appendicitis, routine post-op labs expensive, often unnecessary

    Study: After appendicitis, routine post-op labs expensive, often unnecessary

    [ad_1]

    Newswise — A new study from Yale School of Medicine finds for patients without comorbidities, routine lab work performed after appendectomy for acute appendicitis (AA) significantly increases costs without impacting the course of treatment.

    In a study of 3,711 patients with AA, postoperative labs increased average length of stay from 14.15 hours to 48.28 hours and increased costs by $472.12 per patient. Researchers say routine post-operative labs are likely an unnecessary driver of costs in AA treatment.

    [ad_2]

    Yale School of Medicine

    Source link

  • Red flags indicate risk for early-onset colorectal cancer

    Red flags indicate risk for early-onset colorectal cancer

    [ad_1]

    Newswise — Researchers at Washington University School of Medicine in St. Louis have identified four important signs and symptoms that signal an elevated risk of early-onset colorectal cancer. These red flags may be key to earlier detection and diagnosis of early-onset colorectal cancer among younger adults. The number of young adults with colorectal cancer has nearly doubled in recent years.

    Studying de-identified health insurance data on more than 5,000 patients with early-onset colorectal cancer — cancer that occurs before a person turns 50 — the researchers found that in the period between three months and two years before diagnosis, abdominal pain, rectal bleeding, diarrhea and iron deficiency anemia each indicate an increased risk in those under age 50. They found that having a single one of the symptoms almost doubled the risk; having two symptoms increased risk by more than 3.5 times; and having three or more boosted the risk by more than 6.5 times.

    The study is published May 4 in the Journal of the National Cancer Institute.

    “Colorectal cancer is not simply a disease affecting older people; we want younger adults to be aware of and act on these potentially very telling signs and symptoms — particularly because people under 50 are considered to be at low risk, and they don’t receive routine colorectal cancer screening,” said senior investigator Yin Cao, ScD, an associate professor of surgery in the Public Health Sciences Division, and a research member of Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.

    “It’s also crucial to spread awareness among primary care doctors, gastroenterologists and emergency medicine doctors,” Cao said. “To date, many early-onset colorectal cancers are detected in emergency rooms, and there often are significant diagnostic delays with this cancer.”

    Cao said two symptoms in particular — rectal bleeding and iron deficiency anemia, a condition in which there are not enough healthy red blood cells to carry oxygen — point to the need for timely endoscopy and follow-up.

    In this study, Cao, with first author Cassandra D. L. Fritz, MD, an assistant professor of medicine in the Division of Gastroenterology, and co-first author Ebunoluwa Otegbeye, MD, a general surgery resident, analyzed cases of early-onset colorectal cancer and matched controls using the IBM MarketScan Commercial Database, a big-data tool that provides longitudinal, de-identified information based on health insurance claims data from about 113 million insured adults ages 18 to 64.

    “It usually takes about three months to get a diagnosis from the time a person first goes to the doctor with one or more of the red-flag signs and symptoms we’ve identified,” Fritz said. “But in this analysis, we found that some young adults had symptoms for up to two years prior to their diagnoses. That may be part of the reason many of these younger patients had more advanced disease at the time of diagnosis than what we normally see in older people who get screened regularly.”

    Individuals born in 1990 have double the risk of colon cancer and four times the risk of rectal cancer compared with young adults born in 1950. That trend has prompted the National Cancer Institute, American Cancer Society, American Gastroenterological Association and other professional societies to prioritize research on identifying risk factors and improving early detection. In 2021, the U.S. Preventive Services Task Force lowered the recommended age for colorectal cancer screening from 50 to 45.

    Cao, also an associate professor of medicine, leads a research group focused on identifying risk factors and molecular variations in early-onset colorectal cancer. Her group is among the first to report that obesity, prolonged sitting, metabolic syndrome, diabetes, sugar-sweetened beverages and other risk factors may contribute to the rising incidence of early-onset colorectal cancer.

    According to the American Cancer Society, although the death rate from colorectal cancer has been dropping for several decades in older adults due to regular colonoscopies and improved treatment, more younger people are diagnosed with the disease at advanced stages, and many are dying of the disease.

    Such a shift suggests urgency in recognizing symptoms as early as possible.

    “Since the majority of early-onset colorectal cancer cases have been and will continue to be diagnosed after symptom presentation, it is crucial to recognize these red-flag signs and symptoms promptly and conduct a diagnostic work-up as soon as possible,” Cao said. “By doing so, we can diagnose the disease earlier, which in turn can reduce the need for more aggressive treatment and improve patients’ quality of life and survival rates.”

    Fritz, CDL. Otegbeye EE, Zong X, Demb J, Nickel KB, Olsen MA, Mutch M, Davidson NO, Gupta S, Cao Y. Red-flag signs and symptoms for earlier diagnosis of early-onset colorectal cancer. The Journal of the National Cancer Institute, May 4, 2023.

    The study was funded with support from the National Center for Advancing Translational Sciences, the National Cancer Institute and the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH). Grant numbers: UL1 TR002345, T32 DK007130, T32 CA009621, P30 DK52574 and R37 CA246175.

    About Washington University School of Medicine

    WashU Medicine is a global leader in academic medicine, including biomedical research, patient care and educational programs with 2,800 faculty. Its National Institutes of Health (NIH) research funding portfolio is the third largest among U.S. medical schools, has grown 52% in the last six years, and, together with institutional investment, WashU Medicine commits well over $1 billion annually to basic and clinical research innovation and training. Its faculty practice is consistently within the top five in the country, with more than 1,800 faculty physicians practicing at 65 locations and who are also the medical staffs of Barnes-Jewish and St. Louis Children’s hospitals of BJC HealthCare. WashU Medicine has a storied history in MD/PhD training, recently dedicated $100 million to scholarships and curriculum renewal for its medical students, and is home to top-notch training programs in every medical subspecialty as well as physical therapy, occupational therapy, and audiology and communications sciences.

    [ad_2]

    Washington University in St. Louis

    Source link

  • Achieving Prevention and Health, Rather Than More Healthcare

    Achieving Prevention and Health, Rather Than More Healthcare

    [ad_1]

    Newswise — If more people have access to health insurance, we have to be sure the death rates of those with certain chronic conditions are decreasing.

    This is one of the statements Gregory Peck, an acute care surgeon and associate professor at Rutgers Robert Wood Johnson Medical School, will be researching on behalf of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health.

    Funded by NIH grants totaling more than $1 million through a recent two-year award from the New Jersey Alliance for Clinical and Translational Science (NJ ACTS), a Rutgers hub of the National Center for Advancing Translation Science, and now a four-year award from the NIDDK, Peck is on average one of just two critical care surgeons funded nationally annually creating new models of health for NIH consideration.

    Peck recently published two studies investigating death rates for gallstone disease, a disease of the abdomen that causes right-sided belly pain after eating, which share risk factors with other deadly diseases. His study, published in Gastro Hep Advances, found that between 2009 and 2018 the number of deaths of people in New Jersey with diagnosed gallstone disease (1,580) remained steady and did not improve, and that deaths in Latinos ages 65 and older potentially increased.

    His study in the Journal of Surgical Research found that after Medicaid expansion in 2014 as compared to before, the amount of emergency surgery to remove the gallbladders for gallstone disease decreased in the state overall, but increased in people with Medicaid. While fatality from gallbladder removal surgery decreased for those 65 or older, there was increased death from surgery in the younger population and a trend of more death in the population with Medicaid. Further, the relatively decreased amount of gallbladder removal surgery occurring in ambulatory outpatient care centers did not necessarily help this.

    Peck discusses the implications of the findings on a new shift in healthcare to prevention model.

    Why did you focus on gallstone disease?

    As a metabolic disease, gallstone disease is also linked to heart disease, cancer, diabetes, obesity and a sedentary lifestyle. In fact, heart disease, which is the No. 1 killer in America, and gallstone disease, which is the No. 1 digestive disease requiring surgery in America, share the risk factors of high levels of bad cholesterol type and obesity.

    How do these studies inform public policy?

    The amount of people dying with gallstone disease – most of whom require surgery – over the past decade has not gotten better. That’s 160 people a year who still are dying from a preventable death such as gallstone disease. Making progress is what this type of epidemiologic study focuses on, and concerningly, we might not have made good progress.

    If Medicaid expansion didn’t positively affect the death rate of people with gallstone disease and we see it increase specifically in older Latino populations, we need to be asking if we are helping people of color and those who live in communities with lower socioeconomic status improve health or treating them sooner to prevent emergency surgery and especially decreasing death from emergency surgery. Insurance expansion is certainly needed, but we have to ensure the action specific pieces of policy impact the population requiring surgery in a patient-centered way.

    The real goal is preventing the disease from even occurring. When we pass public health policy, we need to advocate for preventive care that reaches people through their community. Right now, the findings show that we might just be providing people with insurance cards who find themselves still needing to use the emergency department. Instead, that insurance should help them visit their primary care doctor, who can help them make changes like decreasing their bad cholesterol levels, which contribute to gallstone disease, and help them access care in ambulatory surgery centers sooner.

    We need to cultivate preventive healthcare rather than ballooning the investment in emergency healthcare, which does not solve current inequities.

    What other steps to improve access to care should be taken?

    We propose a novel population health approach that shifts from the reactive treatments of emergency disease to proactive prevention. One place to start is increasing access to appropriate outpatient elective healthcare for underrepresented groups with barriers to preventive care, such as by increasing health insurance that incentivizes the behaviors toward improved health. A first step for my research group is to focus on diseases that currently require as much emergency as elective care, such as gallstone disease, and understand this by understanding who presents to the hospital, as to dial this back into the community level, to decrease hospital care.

    In addition, in primary care, laboratory, radiology or ambulatory care settings we need to improve communication with people with low English proficiency – especially how well prevention is explained in a patient’s primary language. Language barriers might also prevent them from understanding the importance of cholesterol or blood pressure control over the one, two and three decades of life, or how they find access to diagnostic tests or treatment needed earlier.

    How is Rutgers working to increase primary care knowledge in underserved communities?

    Shawna Hudson, the co-director of community engagement for NJ ACTS, and my research mentor, is researching how representatives rooted in the community can help healthcare providers and researchers better understand how we can use community engagement to involve people in a communities’ preventive care as to decrease risk factors for chronic disease before they need hospital-based care and, more importantly, emergency surgery.

    One initiative is the Community Engagement Virtual Salons, which help researchers and health care providers at NJ ACTS engage with patients and community members about how biomedical and clinical research leads to action through understanding disease and then enacting policy. In these sessions, the public serves as experts to provide feedback from a community perspective. This allows the medical profession to build relationships with community partners and increase the culturally sensitive participation of hard-to-reach populations.

    [ad_2]

    Rutgers University-New Brunswick

    Source link

  • A healthy microbiome may prevent deadly infections in critically ill people

    A healthy microbiome may prevent deadly infections in critically ill people

    [ad_1]

    Newswise — Twenty to 50 per cent of all critically ill patients contract potentially deadly infections during their stay in the intensive care unit or in hospital after being in the ICU – markedly increasing the risk of death.

    “Despite the use of antibiotics, hospital-acquired infections are a major clinical problem that persists to be a huge issue for which we don’t have good solutions,” says Dr. Braedon McDonald, MD, PhD, an intensive care physician at the Foothills Medical Centre (FMC) and assistant professor at the Cumming School of Medicine (CSM). “We tackled this issue from a different angle. We looked at the body’s natural defense to infection to better understand why some people are more susceptible to these deadly infections.”

    The study involved 51 patients newly admitted to the intensive care unit (ICU) at FMC. Patients were studied over the first week of acute critical illness. The research showed that the gut microbiota and systemic immunity work together as a dynamic “metasystem,” in which problems with gut microbes and immune system dysfunction are associated with significantly increased rates of hospital-acquired infections.

    “The signal that we’ve seen in our research is that a family of bacteria, that naturally live in the gut, seems to be important for directing the immune system,” says Jared Schlechte, PhD candidate in McDonald’s lab and first author of the study. “However, during critical illness the microbiome becomes injured allowing these bacteria to start taking over.”

    The study published in Nature Medicine found that patients who experienced an abnormal increase in the growth of this common bacteria, called a bloom, were at the highest risk of severe infections.

    “This information is important because it gives us a whole new avenue to start thinking about not just ways to treat infections, but a potential treatment to prevent them,” says McDonald. “The findings suggest that if we want to fight infection, we can’t just target these bad bacteria in isolation and the immune system in isolation. We really need to have a more holistic view of how things are functioning.” McDonald says the study’s findings

    As a next step, McDonald and the team plan to launch a randomized, controlled clinical trial – based on a precision medicine approach that borrows from probiotics therapy, and utilizes multiple different bacteria engineered to specifically target the bacteria identified in the study. People who agree to participate will be given engineered microbiomes.

    “What we’re trying to do is restore the normal mechanism that work when we’re healthy, and take advantage of that to help protect people from infections,” McDonald says.

    UCalgary faculty co-authors included Drs. Christopher Doig, MD, Kathy McCoy, PhD, and Mary Dunbar, MD. PhD candidate Amanda Zucoloto, along with research technician and laboratory manager Ian-Ling Yu, also co-authored the study. The study was supported by the Canadian Institutes of Health Research and the Alberta Health Services Critical Care Strategic Clinical Network

    Braedon McDonald is an assistant professor in the Department of Critical Care Medicine at the Cumming School of Medicine (CSM), an intensive care physician at the Foothills Medical Centre, and a member of the Snyder Institute for Chronic Diseases at CSM.

    The Snyder Institute for Chronic Diseases is a team of more than 480 clinician-scientists and basic scientists dedicated to uncovering new knowledge leading to disease prevention, tailored medical applications and ultimately cures for those with chronic and infectious disease. Visit snyder.ucalgary.ca and follow @SnyderInstitute to learn more.

    [ad_2]

    University of Calgary

    Source link

  • Technology to protect bioactive compounds from food during digestion

    Technology to protect bioactive compounds from food during digestion

    [ad_1]

    Newswise — Bioactive compounds present mostly in fruit and vegetables perform different bodily functions relating to health and well-being. Their effects are considered antioxidant, antidiabetic, antiaging and anticancer, among others.

    Many studies are looking for ways to optimize absorption of bioactive compounds by the organism and increase their bioavailability – the proportion that enters the bloodstream after absorption. One way is to coat the compounds with another material and package them on the nanometric scale (a nanometer is a billionth of a meter). Nanoencapsulation, as this technique is known, assures slow release of the compounds so that they take longer to digest and can survive the attacks of bacteria in the gut microbiome.

    An investigation conducted by a duo of researchers at the University of São Paulo’s School of Pharmaceutical Sciences (FCF-USP) in Brazil is one of these studies. Working at the school’s Department of Food Science and Experimental Nutrition, they have produced several articles on the subject – the latest of which, published in the International Journal of Biological Macromolecules, is a review of the literature on pectin-based nanoencapsulation plus a description of a novel technology developed under the aegis of the Food Research Center (FoRC), a Research, Innovation and Dissemination Center (RIDCsupported by FAPESP.

    “We used pectin extracted from residues of citrus fruit albedo and peel, with a degree of purity permitting human ingestion and excluding any kind of hazardous chemical,” said João Paulo Fabi, one of the authors and a professor at FCF-USP. Albedo is the layer of white spongy material inside the peel of oranges and lemons, for example.

    “In addition to our review of the literature, we describe a novel technology for nanoencapsulation of bioactive compounds using pectin. This entails producing a pectin-lysozyme complex as a protective outer layer for a highly sensitive bioactive compound called anthocyanin,” he explained, adding that lysozyme is “a safely edible substance obtained from egg white and used to enhance the stability of the end-product”.

    Anthocyanins are water-soluble pigments belonging to the flavonoid family. They are phenolic compounds found in all plants and responsible for the shades of red, blue and purple seen in flowers, fruit, leaves, stalks and roots.

    The authors say their methodology can be used to encapsulate other water-soluble bioactive compounds. “We tested anthocyanin because of its challenging sensitivity to many factors, such as light, temperature, pH and gut bacteria,” said Thiécla Katiane Osvaldt Rosales, the other author. She is currently a postdoctoral researcher at the Nuclear and Energy Research Institute (IPEN).

    Besides FoRC, FAPESP also funded the research via support for two other projects (19/11816-8 and 12/23970-2). 

    Advantages of methodology

    According to the researchers, the main advantage of their methodology is that no other compounds are added apart from pectin, lysozyme and anthocyanin. “We used three compounds from sources in nature and mixed them in the laboratory to form a new product, without adding salts, ligands or anything potentially toxic. Furthermore, the nanoparticles are not too small. Very tiny nanoparticles can penetrate barriers and cell membranes, entering the DNA and having toxic effects. The size we obtained is safe,” Fabi said.

    Rosales outlined the process they developed to produce the nanoparticles. “Pectin and lysozyme are heated separately. The increase in temperature partly alters their structure, and they interact better when heated. They are then rapidly cooled to reach a temperature not harmful to anthocyanin, which is sensitive and fairly unstable. The three substances are blended in an aqueous suspension and agitated for an hour. The result is encapsulated anthocyanin. The suspension is then filtered to separate the non-encapsulated contents,” she said.

    Special care is taken with factors such as temperature and pH. “We tested the parameters for the purpose of optimization, especially pH. If pH is too high, the anthocyanin breaks down. It can’t be too low, either. We found a pH of 5 to be optimal for interaction between the molecules,” she explained. “We also tested the duration and intensity of the agitation. We made a point of managing all the details, however minor, because they make a difference in terms of forming stable particles. We’ve applied for a patent on the methodology.”

    Results

    Finally, the encapsulation was tested for efficacy in a digestion system simulated in the laboratory to mimic the gastric and intestinal phases. “The result was that part of the anthocyanin was released during the digestive process, at the end of gastric digestion, and part remained in the nanostructure, with the possibility of release of this remainder in the gut or absorption together with the nanostructure. We believe this was a good outcome. Partial and gradual release suggests absorption of the compound starts before it enters the gut, with the nanoencapsulated remainder probably being released in the gut or fully absorbed with less structural alteration,” Rosales said.

    The next step will be animal testing. “We tested the method in vitro and obtained results indicating that the nanoparticles are safe for consumption. We have evidence that cells can absorb them in a non-toxic manner and that the pectin protects the anthocyanin and its properties. We now have to test it in animals, observing the process of oral ingestion, absorption of the anthocyanin using specific markers for absorption, and the route followed in the organism. It’s important to verify the extent of absorption and the biological destination,” she said.

    The nanoparticles are mainly intended for use as a food supplement. “They can be added to food and dietary supplements, but industrial mass production would be necessary to include them in a supplement,” Fabi said.

    It is worth noting that the method does not require expensive equipment or procedures. “In addition, the material used for the nanocapsules, which comes from byproducts of citrus peel, would make the cost even lower for manufacturers. The pectin we used in our study is available commercially and is used by the food industry, mostly for gel formation in jam or as a thickener,” Rosales said.

    About São Paulo Research Foundation (FAPESP)

    The São Paulo Research Foundation (FAPESP) is a public institution with the mission of supporting scientific research in all fields of knowledge by awarding scholarships, fellowships and grants to investigators linked with higher education and research institutions in the State of São Paulo, Brazil. FAPESP is aware that the very best research can only be done by working with the best researchers internationally. Therefore, it has established partnerships with funding agencies, higher education, private companies, and research organizations in other countries known for the quality of their research and has been encouraging scientists funded by its grants to further develop their international collaboration. You can learn more about FAPESP at www.fapesp.br/en and visit FAPESP news agency at www.agencia.fapesp.br/en to keep updated with the latest scientific breakthroughs FAPESP helps achieve through its many programs, awards and research centers. You may also subscribe to FAPESP news agency at http://agencia.fapesp.br/subscribe.

    [ad_2]

    Sao Paulo Research Foundation (FAPESP)

    Source link

  • Raising Awareness About Colorectal Cancer

    Raising Awareness About Colorectal Cancer

    [ad_1]

    Newswise — With the arrival of March, Colorectal Cancer Awareness Month, faculty and staff in the Department of Internal Medicine’s Section of Digestive Diseases are redoubling their efforts to spread the word about the importance of screening, especially in younger individuals and those with a family history of the disease.

    Colorectal cancer is the second most common cause of cancer death in the United States. Still, many people are unaware of the role screening plays in reducing their risk of developing the disease.

    “Caught early, this cancer has an excellent prognosis, and screening has been shown to decrease incidence and mortality,” said Xavier Llor, MD, PhD, professor of medicine (digestive diseases), Yale School of Medicine; medical director of the Cancer Screening and Prevention Program and Colorectal Cancer Prevention Program at Smilow Cancer Hospital and Yale Cancer Center.

    Despite the continued overall decline of colorectal cancer, recent statistics are worrisome, Llor said. According to the latest report from the American Cancer Society, the proportion of cases among those younger than 55 has increased and the progress against colorectal cancer as a whole has slowed.

    Llor recommends that health care providers start the discussion with patients by age 40, to increase the chances that they will get screened by 45. Individuals with a parent, sibling, or child who had colorectal cancer should start screening earlier, at age 40, he said.

    “It takes time and repeated reminders for many people to finally have a colorectal cancer screening done,” he said. “If we promote awareness together, with the help of general practitioners, we can make a difference.”

    Since forming one of the nation’s first sections of hepatology and then gastroenterology over 50 years ago, Yale’s Section of Digestive Diseases has had an enduring impact on research and clinical care in gastrointestinal and liver disorders. To learn more about their work, visit Digestive Diseases.

    [ad_2]

    Yale Cancer Center/Smilow Cancer Hospital

    Source link

  • AI used to predict future flares of ulcerative colitis activity

    AI used to predict future flares of ulcerative colitis activity

    [ad_1]

    Newswise — Ulcerative colitis assessment could be improved after new research shows that an artificial intelligence model could predict flare-ups and complications after reading biopsies.

    In a new paper published in Gastroenterology today (Friday 3 March), researchers supported by the National Institute for Health and Care Research Birmingham Biomedical Research Centre have trialled an AI diagnostic tool that can read digitised biopsies taken during colonoscopy.

    The Computer-Aided Diagnostic model was able to predict the risk of flare-ups for ulcerative colitis, which is a relapsing-remitting condition and makes the prognosis for the disease uncertain. In the trial, the model was able to predict patients at risk of a flare in the disease as well as humans.

    The system was trained on existing digitised biopsies and was able to detect activity related to ulcerative colitis with 89% accuracy for positive results. It was also able to identify markers of inflammation activity and healing in the same area as biopsies were taken with 80% accuracy, similar to human pathologists.

    Professor Marietta Iacucci from the Institute of Immunology and Immunotherapy at the University of Birmingham and University College Cork in Ireland, and co-lead author of the paper said:

    “The power of AI in healthcare is evident in trials like these, where a model can be used to standardize in real-time histological assessment of Ulcerative Colitis disease activity. But most importantly it provides analytical support and enables clinicians to support those at the greatest risk of relapsing symptoms and disease course.

    “Ulcerative Colitis is a complex condition to predict, and developing machine learning-derived systems to make this diagnostic job quicker and more accurate could be a game changer. As models like this further develop, the predictive quality is likely to improve even more, and our paper demonstrates how beneficial such technology could be for clinicians and, crucially patients.”

    [ad_2]

    University of Birmingham

    Source link